Zacks: Analysts Expect OrthoPediatrics Corp. (NASDAQ:KIDS) Will Post Quarterly Sales of $32.87 Million

Brokerages expect OrthoPediatrics Corp. (NASDAQ:KIDSGet Rating) to post $32.87 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for OrthoPediatrics’ earnings, with the lowest sales estimate coming in at $31.80 million and the highest estimate coming in at $33.78 million. OrthoPediatrics posted sales of $26.70 million in the same quarter last year, which suggests a positive year over year growth rate of 23.1%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that OrthoPediatrics will report full year sales of $123.46 million for the current year, with estimates ranging from $122.96 million to $123.93 million. For the next fiscal year, analysts forecast that the company will post sales of $148.75 million, with estimates ranging from $147.81 million to $149.73 million. Zacks’ sales averages are an average based on a survey of analysts that cover OrthoPediatrics.

OrthoPediatrics (NASDAQ:KIDSGet Rating) last posted its quarterly earnings results on Wednesday, March 2nd. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.05. OrthoPediatrics had a negative return on equity of 7.04% and a negative net margin of 14.98%. The firm had revenue of $24.81 million during the quarter, compared to analysts’ expectations of $24.78 million. During the same quarter in the previous year, the business earned ($0.31) earnings per share.

A number of equities analysts recently issued reports on KIDS shares. Piper Sandler dropped their price objective on shares of OrthoPediatrics from $80.00 to $55.00 in a report on Thursday, May 5th. TheStreet downgraded shares of OrthoPediatrics from a “c” rating to a “d+” rating in a report on Thursday, May 5th. Needham & Company LLC dropped their price objective on shares of OrthoPediatrics from $83.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday, March 3rd. Truist Financial decreased their target price on shares of OrthoPediatrics from $70.00 to $54.00 in a research note on Friday, May 6th. Finally, Zacks Investment Research upgraded shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 17th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $66.00.

OrthoPediatrics stock opened at $41.32 on Wednesday. The stock has a market cap of $835.90 million, a PE ratio of -53.66 and a beta of 0.88. The stock has a fifty day moving average of $48.52 and a 200 day moving average of $52.68. OrthoPediatrics has a one year low of $36.71 and a one year high of $73.91.

In other OrthoPediatrics news, CEO David R. Bailey sold 4,078 shares of OrthoPediatrics stock in a transaction on Wednesday, March 2nd. The shares were sold at an average price of $58.10, for a total transaction of $236,931.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 3,918 shares of OrthoPediatrics stock in a transaction on Wednesday, March 2nd. The stock was sold at an average price of $58.46, for a total transaction of $229,046.28. The disclosure for this sale can be found here. Insiders sold 22,984 shares of company stock worth $1,334,452 in the last 90 days. 30.30% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of KIDS. Point72 Hong Kong Ltd purchased a new position in OrthoPediatrics during the first quarter worth $26,000. Confluence Wealth Services Inc. purchased a new position in OrthoPediatrics during the fourth quarter worth $28,000. UBS Group AG boosted its stake in shares of OrthoPediatrics by 106.4% during the third quarter. UBS Group AG now owns 421 shares of the company’s stock valued at $28,000 after purchasing an additional 217 shares during the period. Sageworth Trust Co of South Dakota purchased a new stake in shares of OrthoPediatrics during the fourth quarter valued at $43,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of OrthoPediatrics during the first quarter valued at $65,000. 71.51% of the stock is owned by institutional investors.

About OrthoPediatrics (Get Rating)

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

Read More

Get a free copy of the Zacks research report on OrthoPediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.